NCT03220334 is a Phase 3 clinical trial of Platelet rich plasma in Platelet-rich Plasma, sponsored by Keimyung University Dongsan Medical Center.

Who is sponsoring NCT03220334?

NCT03220334 is sponsored by Keimyung University Dongsan Medical Center.

What drugs are being tested in NCT03220334?

Interventions in NCT03220334: Platelet rich plasma, Normal saline.

What condition does NCT03220334 study?

NCT03220334 studies Platelet-rich Plasma, Endoscopic Submucosal Dissection.

Is NCT03220334 still recruiting?

NCT03220334 is currently completed. Last updated 7 November 2017.

Last reviewed 2017-11-07 · How we verify

NCT03220334

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Healing Effects of Autologous Platelet Rich Plasma on Gastric Ulcer Caused by Endoscopic Submucosal Dissection

Completed Phase 3 Last updated 7 November 2017

What this trial tests

Phase 3 trial testing Platelet rich plasma in Platelet-rich Plasma in 20 participants. Completed in 31 October 2017.

Timeline

1 June 2017

Primary endpoint
31 October 2017

31 October 2017

Quick facts

Lead sponsor	Keimyung University Dongsan Medical Center
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	20
Start date	1 June 2017
Primary completion	31 October 2017
Estimated completion	31 October 2017
Sites	1 location across South Korea

Drugs / interventions tested

Platelet rich plasma — full drug profile →
Normal saline

Conditions studied

Platelet-rich Plasma — all drugs for Platelet-rich Plasma →
Endoscopic Submucosal Dissection — all drugs for Endoscopic Submucosal Dissection →

Sponsor

Keimyung University Dongsan Medical Center

Who can join

18 and older, any sex, with Platelet-rich Plasma or Endoscopic Submucosal Dissection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In Korea, where the prevalence of gastric tumors is high, the use of ESD as a treatment for gastric cancer will continue to increase. Considering that there are no special measures to prevent side effects (bleeding, perforation, etc.) of this procedure, it is possible to reduce the large medical costs through the discovery of substances that can promote gastric mucosal healing. Mechanism of PRP-based materials in the regeneration of gastric mucosal damage can be used to understand the pathophysiology of ulcers. In the future, it can be suggested as a new treatment for gastrointestinal tract damage such as intractable ulcer, perforation, mucosal fistula, gastrointestinal bleeding caused by esophagus, small intestine and large intestine as well as ulcer treatment by endoscopic procedure.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

UEG Week 2018 Poster Presentations
· 2018 · cited 2×

Verify or expand the search:

Other trials of Platelet rich plasma

Trials testing the same drug.

NCT06510673 — Extracorporeal Shock Wave Therapy Versus High Power LASER Therapy for the Treatment of Females With Calcaneal Spur · NA · not yet recruiting
NCT06532318 — Comparative Study Between Platelet Rich Plasma and Steroid Injection in Trigger Finger Treatment · Phase 3 · not yet recruiting
NCT06814535 — A Comparative Study on the Impact of Trigger Points Injection of Platelet Rich Plasma Versus Botulinum Toxin on the Reli · Phase 2, PHASE3 · active not recruiting
NCT06440655 — The Efficacy and Safety of Platelet-rich Fibrin and Platelet Rich Plasma in Female Pattern Hair Loss Patients · NA · recruiting
NCT05479474 — Platelet Rich Plasma Testis Treatment for Infertile Men · NA · recruiting

Other recruiting trials for Platelet-rich Plasma

Currently open trials in the same condition.

NCT06492213 — The Efficacy and Safety of Pulsed Radiofrequency Combined With Platelet-rich Plasma for Infraorbital Neuralgia · recruiting

Other Keimyung University Dongsan Medical Center trials

Trials by the same sponsor.

NCT06963424 — Pain Relief and and Peripheral Perfusion Index During Erector Spinae Block · NA · completed
NCT06471907 — Comparison of Pain Relief and Peripheral Perfusion Index · NA · recruiting
NCT07210073 — Video Education to Improve Blood Pressure Control in Patients With Ischemic Heart Disease and Hypertension (V-EDUCATE) · NA · completed
NCT06149299 — Great Occipital Nerve Block Using Different Approach · NA · unknown
NCT05705362 — Simple Crossover Versus Side Branch Opening in Patients With Non-Left Main Bifurcation Lesion · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03220334 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Keimyung University Dongsan Medical Center
Last refreshed: 7 November 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03220334.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing